Diabetic chronic ulcers, a common complication of diabetes, are significant cause of morbidity and mortality in the Western world.
Despite the considerable medical need, currently no specific and efficacious treatment for diabetic -and other chronic- ulcers exist.
This is in part due to the complexity of the condition and incompletely understood mechanisms underlying delayed wound healing.
We have found that increased expression of a protease inhibitor SerpinB3 is associated with faster healing of ulcers in diabetic patients and showed that topical administration of exogenous SerpinB3 facilitates wound healing in mice.
To this end, we developed a novel semisolid formulation suitable for topical administration of protein-based bioactive agents. The carrier allows to overcome problems related to the intrinsic instability or proteins in aqueous environment and permits their sustained release for more that 3 days. Topical administration of SerpinB3 was effective in promoting chronic wound healing only if administered in this slow releasing formulation.

TRL (Technology Readiness Level)

Lead Optimization/Preclinical

Inventors

Patrizia
Pontisso

Margherita
Morpurgo

GianPaolo
Fadini

Mattia
Albiero

Alessandra
Biasiolo

Santina
Quarta

Mariagrazia
Ruvoletto

Cristian
Turato

Gianmarco
Villano

Download the brochure

  • A compound to mitigate the cytokine storm

    The body’s inflammatory response to fight infections and in tissue repair processes is crucial for normal functioning of the body. Yet, if not controlled, it can cause severe injury to the human body, as occurs during cytokine storm, a potentially[...]

  • INSERT – SerpinB3 inhibitor for tumor treatment

    Expression of SerpinB3, a member of serine-protease inhibitor family, is associated with the carcinogenesis process as it determines resistance to apoptosis, induces cell proliferation and greater cell invasiveness. Furthermore, it leads to impaired immune surveillance and reduced chemosensitivity. Recent studies[...]

  • Bicyclic peptides for targeted therapy against cancer

    Since inhibitors based on small molecules and macromolecules are not selective and potent enough, new compounds, including bicyclic peptides, have been developed in recent years. Bicyclic peptides are new generation therapeutic molecules which exhibit properties typical of monoclonal antibodies (high[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation